Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer
Table 3
Univariate analysis of factors associated with the KRAS/NRAS/BRAF status.
Factors
Mutated group
Wild-type group
Gender
0.657
Male
25
26
Female
21
13
Age, years
0.249
>59
23
27
≤59
23
12
BMI
0.342
Mean ± SD
21.96 ± 3.57
21.98 ± 2.78
Tumor location
0.288
Left hemicolon
17
16
Right hemicolon
14
8
Rectum
15
15
Histologic type
0.711
Nonmucinous adenocarcinoma
45
38
Mucinous adenocarcinoma
1
1
Differentiation
0.497
Well/moderate
39
35
Poor
7
4
UICC-TNM stage
0.406
I/II
16
17
III/IV
30
22
T-category
0.421
Tis, T1, T2
0
4
T3, T4
46
35
N-category
0.354
Positive
38
29
Negative
8
10
M-category
0.534
Positive
35
21
Negative
11
18
Tumor size, mm
0.406
Mean ± SD
49.87 ± 27.11
48.41 ± 29.70
SUVmax in tumor
0.012
Mean ± SD
15.40 ± 6.47
12.59 ± 5.79
SUV in normal liver
0.597
Mean ± SD
1.97 ± 0.43
1.87 ± 0.36
T/NT
0.004
Mean ± SD
7.87 ± 2.94
6.26 ± 2.83
UICC: Union for International Cancer Control; SUVmax: maximum standardized uptake value; BMI: body mass index; T/NT: target lesion to nontarget lesion ratio.
